Clinical Trials Logo

Clinical Trial Summary

This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03514420
Study type Interventional
Source Akcea Therapeutics
Contact
Status Completed
Phase Phase 2
Start date June 15, 2018
Completion date August 21, 2019

See also
  Status Clinical Trial Phase
Completed NCT02654977 - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Phase 2
Completed NCT03508687 - Study of Gemcabene in Adults With FPLD Phase 1/Phase 2
Completed NCT02430077 - Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients Phase 2
Terminated NCT05088460 - A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) Phase 2
Terminated NCT02527343 - The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy Phase 2/Phase 3
Available NCT02404896 - Expanded Access Metreleptin Study